Experimental drug shields against gluten damage
An early trial of the drug A.N.P.033, manufactured by First Trax Biotherapeutics, demonstrated that it protects celiac patients from intestinal damage caused by gluten exposure and prevents symptom worsening despite adherence to a gluten-free diet. The study involved 32 patients following a gluten-free regimen, and results showed that patients who received the drug significantly avoided intestinal damage and symptom escalation compared to the placebo group, with only 6% needing medication to alleviate symptoms versus 47% in the placebo group. These findings represent the first evidence of the drug's ability to shield the intestines from gluten-related harm in celiac disease patients.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)